Filing Details

Accession Number:
0001209191-15-066998
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-08-19 20:01:27
Reporting Period:
2015-08-17
Filing Date:
2015-08-19
Accepted Time:
2015-08-19 20:01:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1479290 Revance Therapeutics Inc. RVNC Pharmaceutical Preparations (2834) 770551645
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1597578 Curtis Ruegg C/O Revance Therapeutics, Inc.
7555 Gateway Boulevard
Newark CA 94560
Evp, Technical Operations No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-08-17 3,000 $8.70 21,027 No 4 M Direct
Common Stock Disposition 2015-08-17 1,000 $30.13 20,027 No 4 S Direct
Common Stock Disposition 2015-08-17 500 $30.27 19,527 No 4 S Direct
Common Stock Disposition 2015-08-17 500 $30.60 19,027 No 4 S Direct
Common Stock Disposition 2015-08-17 500 $30.43 18,527 No 4 S Direct
Common Stock Disposition 2015-08-17 400 $30.18 18,127 No 4 S Direct
Common Stock Disposition 2015-08-17 100 $31.35 18,027 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2015-08-17 3,000 $0.00 3,000 $8.70
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
55,836 2023-05-26 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2014.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $30.225, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.135 to $30.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.46 to $30.675, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $30.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 to $30.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  7. The shares subject to this Option vest in 48 equal monthly installments over 4 years following May 27, 2013.